Press release
Peraso (NASDAQ: PRSO) Pushes Back on Mobix Labs (NASDAQ: MOBX) Takeover Bid, Valuation, Nasdaq Compliance Etc. - More Stocks Inside
Peraso Inc. (NASDAQ: PRSO), a leading innovator in mmWave wireless solutions, has officially acknowledged receipt of an unsolicited, non-binding acquisition proposal from Mobix Labs, Inc. (NASDAQ: MOBX). The offer proposes a stock-for-stock exchange that values Peraso at approximately $1.20 per share, representing a 20% premium over its 30-day average closing price. However, Peraso is contesting several key points made in Mobix's June 26 press release.Financials Mischaracterized, Says Peraso
Peraso rebuffed Mobix's suggestion that the company is generating only $1.5 million in quarterly revenue from mmWave products. According to Peraso, its total Q1 2025 revenue was approximately $3.8 million, with full-year 2024 revenue reaching $14.2 million-figures that are materially higher than those cited by Mobix.
The company directed investors to its SEC filings, including the 2024 10-K and Q1 2025 10-Q, which provide audited and reviewed financials. "These filings remain the authoritative source for Peraso's financial performance," the company stated.
Nasdaq Compliance Addressed
Mobix also claimed that Peraso risks Nasdaq delisting unless it achieves a $35 million market cap by November 2025. Peraso categorically denied this, clarifying that it is currently in compliance with Nasdaq's listing rules under Rule 5550(b)(1) by maintaining stockholders' equity above $2.5 million, an alternative path to continued listing. The company called Mobix's assertion "incorrect" and "potentially misleading."
In addition to Peraso Inc.'s (NASDAQ: PRSO) acquisition news today keep an eye on other stocks: Globavend Ltd (NASDAQ: GVH), Bone Biologics Corp (NASDAQ: BBLG), NanoVibronix Inc. (NASDAQ: NAOV), SaverOne 2014 Ltd. (NASDAQ: SVRE), Nuburu Inc. (NASDAQ: BURU) and Synergy Corp. "Focusfactor" (NASDAQ: SNYR) as they are moving aggressively in early trading today.
Board Evaluation and Response
Peraso's Board of Directors is evaluating all strategic options to maximize shareholder value and has not yet accepted or rejected Mobix's offer. The company emphasized its commitment to acting in the best interests of shareholders and is working closely with legal and financial advisors to assess the proposal.
"This offer significantly undervalues Peraso's mmWave leadership and growth trajectory," one source close to the company noted. "We believe Peraso has the momentum and foundation to create far greater long-term value than the $1.20 per share offer suggests."
The company added it will not provide ongoing commentary on potential M&A activity unless legally required, and there is no guarantee that a transaction with Mobix-or any other party-will materialize.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=peraso-nasdaq-prso-pushes-back-on-mobix-labs-nasdaq-mobx-takeover-bid-valuation-nasdaq-compliance-etc-more-stocks-inside]
Country: United States
Website: http://www.thestreetreports.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Peraso (NASDAQ: PRSO) Pushes Back on Mobix Labs (NASDAQ: MOBX) Takeover Bid, Valuation, Nasdaq Compliance Etc. - More Stocks Inside here
News-ID: 4085608 • Views: …
More Releases from ABNewswire

Systemic Mastocytosis Pipeline Insight 2025: Targeted KIT Inhibitors, Novel Path …
The systemic mastocytosis pipeline is progressing quickly due to the urgent need for effective treatments targeting KIT mutations, especially KIT D816V. Current options mostly offer symptom relief, while approved targeted therapies help but fall short in aggressive cases-highlighting the need for more durable, disease-modifying treatments.
DelveInsight's "Systemic Mastocytosis - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/systemic-mastocytosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" explores a robust pipeline of emerging drugs poised to reshape the treatment paradigm. Next-generation KIT inhibitors with improved…

Status Epilepticus Pipeline Insight 2025: Precision Rescue Therapies, Next-Gen A …
The treatment pipeline for status epilepticus is advancing rapidly due to the condition's high mortality and limited treatment options. Current therapies, like benzodiazepines and IV antiseizure drugs, often have delayed effects, toxicity risks, and limited efficacy in refractory cases, highlighting the need for safer, faster, and more targeted solutions.
DelveInsight's "Status Epilepticus - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/status-epilepticus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" highlights a diverse wave of clinical and preclinical candidates addressing these gaps. Novel rescue…

Magnetic Resonance Imaging Devices Market Poised to Register a CAGR of ~6.54% by …
The MRI devices market is set to grow steadily, driven by the rising prevalence of chronic diseases, demand for non-invasive diagnostics, and technological innovations that enhance imaging accuracy, speed, and patient comfort. MRI continues to play a critical role across oncology, cardiology, neurology, and musculoskeletal care.
On September 11, 2025, Tempus AI, Inc. (NASDAQ: TEM) received FDA 510(k) clearance for its updated Tempus Pixel, an AI-powered cardiac imaging platform. The upgrade…

Blood Pressure Monitoring Devices Market to Register a CAGR of ~10.01% by 2032, …
The blood pressure monitoring devices market is poised for significant growth, driven by the rising global prevalence of hypertension, lifestyle-related risks, and the growing focus on early detection and preventive care. As cardiovascular diseases remain the leading cause of death worldwide, demand for accurate and user-friendly monitoring solutions-ranging from traditional cuffs to digital and wearable devices-is increasing across hospitals, clinics, home care, and remote monitoring settings.
In a landmark development, the…
More Releases for Peraso
Undervalued Tech: Peraso Inc's (NASDAQ: PRSO) True Value Signals Upside - More S …
Mobix Labs recently made the kind of mistake that reveals more about the bidder than the target. Their unsolicited acquisition [https://www.stocktitan.net/news/PRSO/peraso-confirms-receipt-of-unsolicited-non-binding-acquisition-pevb9rjomb71.html] offer for Peraso represents classic bottom-feeding behavior. A 20% premium that exploits market pressure rather than recognizing strategic value.
This follows their established pattern of lowball offers to multiple companies. Mobix declined to sign standard confidentiality agreements, indicating they never intended serious due diligence. The timing reveals everything. PerasoInc's (NASDAQ:…
Peraso Inc. (NASDAQ: PRSO) Signals Turnaround - Reports Financials August 11, 20 …
Peraso Inc. (NASDAQ: PRSO) a fundamental growth story-driven by military contracts, commercial wins, and sector diversification-is even more compelling. Over the past year, Peraso has strategically expanded its footprint, building a foundation for long-term growth powered by its proprietary 60GHz mmWave technology.
Defense Sector: Stealthy Solutions for Modern Battlefields
Peraso Inc.'s (NASDAQ: PRSO) entry into the defense sector marks a key inflection point, with its Perspectus module-featuring stealth, low-jamming, narrow-beamforming, and week-long…
Peraso (NASDAQ: PRSO) Volume Surges on Takeover News - More Stocks Inside
Mobix Labs, Inc. (NASDAQ: MOBX) has launched an unsolicited, non-binding proposal to acquire Peraso Inc. (NASDAQ: PRSO) in a stock-for-stock deal offering Peraso shareholders a 20% premium over the company's 30-day average share price.
The proposed merger would create a stronger player in the high-growth mmWave, defense, and 5G semiconductor sectors-combining Mobix's $10.7M revenue base and ~450% YoY growth with Peraso's accelerating mmWave performance. The combined company is expected to generate…
Peraso Inc.'s (NASDAQ: PRSO) Beamforming Technology Gains Military Traction - Se …
Peraso Inc.'s (NASDAQ: PRSO) advanced beamforming technology has proven to be a game-changer in military and dense urban deployments, where secure, reliable, and high-performance communication is critical. Beamforming's ability to direct signals with precision and bend them around obstacles not only maximizes efficiency but also makes transmissions exceptionally difficult to detect or intercept. These stealth capabilities, combined with Peraso's proprietary innovations, have enabled its solutions to excel in active war…
Peraso Inc.'s (NASDAQ: PRSO) PERSPECTUS Modules Outperform in 60Ghz FWA Market
Introduction
As high-speed internet access spreads around the world, the unlicensed 60GHz (57-71 Ghz) millimeter-wave (mmWave) spectrum offers immense potential for low-cost, low-capex, easily-deployed high-speed wireless communication, especially areas currently underserved by traditional broadband distribution-fiberoptic. Further, However, until recently, purchasing devices to adequately provide mmWave communications for 60Ghz/mmWave broadband deployments has been difficult. Peraso and several other companies have developed and ramped up mass manufacturing of viable 60Ghz solutions for this…
Peraso Inc. (NASDAQ: PRSO) Director Invests $127K, Ladenburg Thalmann Coverage, …
On Tuesday, June 11th, Peraso Inc. (NASDAQ: PRSO) Director Ian McWalter acquired 100,000 shares of the company's stock at an average price of $1.27 per share, totalling $127,000. This strategic investment increases McWalter's holdings to 101,246 shares.
Image: https://www.abnewswire.com/uploads/9a500d398df4ec1d757968c73f802240.jpg
On June 12, 2024, Ladenburg Thalmann, a renowned Wall Street firm since 1876, initiated coverage [https://thestreetreports.com/wp-content/uploads/2024/06/PRSO-Updated-research.pdf] of Peraso Inc. (NASDAQ: PRSO). Research by Grandview Research in January 2024 highlighted the global mmWave market's…